# US 2021/0198345 A1 · Peptide construct having a protease-cleavable linker

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0198345 A1
- Document ID: US20210198345A1
- Status: Published application
- Kind: A1
- Application number: 17/196,498
- Filed: 2021-03-09
- Published: 2021-07-01
- Earliest claimed: 2015-03-31
- Assignees: VHsquared Limited
- Applicants: Vhsquared Limited
- Inventors: Scott Crowe; Mike West; Kevin Roberts
- Web page: https://patentgrep.com/patent/US20210198345A1

## CPC

- C07K 16/1282: Clostridium (G)
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 16/241: {Tumor Necrosis Factors}
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/64: comprising a combination of variable region and constant region components
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K 2319/50: containing protease site
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

There is provided inter alia a construct suitable for oral administration comprising a first polypeptide and a second polypeptide connected by a labile peptide linker, wherein the labile peptide linker is labile to one or more proteases present in the intestinal tract and wherein the first and second polypeptides are substantially resistant to said one or more proteases.

## Claims

### Claim 1

A method of making a construct comprising a first immunoglobulin chain variable domain and a second immunoglobulin chain variable domain connected by a labile peptide linker, wherein:
(i) the peptide linker is labile to one or more proteases present in the intestinal tract,
(ii) the peptide linker is stable to yeast proteases and
(iii) the first and second immunoglobulin chain variable domains are substantially resistant to said one or more proteases;
comprising the step of producing the construct in yeast.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the yeast is S. cerevisiae.

### Claim 3 (depends on 1)

The method according claim 1, wherein the labile peptide linker is labile to one or more proteases present in the intestinal tract such that greater than 50% by mass of the construct is cleaved into first and second immunoglobulin chain variable domains after 160 minutes after mixing in the Trypsin Protease Assay.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the labile peptide linker is stable to yeast proteases such that no more than 10% by mass of the construct is cleaved into first and second immunoglobulin chain variable domains after producing the construct using the Yeast Expression Protocol.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the first immunoglobulin chain variable domain and the second immunoglobulin chain variable domain are substantially resistant to one or more proteases present in the intestinal tract such that at least 70% by mass of the first immunoglobulin chain variable domain and at least 70% by mass of the second immunoglobulin chain variable domain remain uncleaved after 10 minutes after mixing in the Trypsin Protease Assay.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the one or more proteases are present in the small or large intestine.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the labile peptide linker comprises a cleavage site for trypsin or a trypsin-like protease.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the labile peptide linker comprises at least 1 K residue.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the labile peptide linker comprises at least 1 R residue.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the labile peptide linker has a length of at least 3 residues.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the labile peptide linker has a length of no greater than 40 residues.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the labile peptide linker comprises of a polypeptide sequence of the format:
[-(GaS)x-B-(GbS)y-]z
wherein
a is 1 to 10;
b is 1 to 10;
x is 1 to 10;
y is 1 to 10;
z is 1 to 10 and
B is K or R.

### Claim 13 (depends on 1)

The method according to claim 1, wherein the labile peptide linker comprises of a polypeptide sequence of the format:
-B-(GaS)x-B′-
wherein
a is 1 to 10;
x is 1 to 10;
B is K or R and
B′ is K or R.

### Claim 14 (depends on 1)

The method according to claim 1, wherein the first immunoglobulin chain variable domain binds to a first target accessible via the intestinal tract.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the first target is a first deleterious agent originating from an intestinal tract resident pathogenic microbe.

### Claim 16 (depends on 14)

The method according to claim 14, wherein the first target is selected from the group consisting of: an interleukin, an interleukin receptor, a transcription factor, a cytokine, a transmembrane protein, a surface glycoprotein, a soluble protein, an integrin, an adhesion molecule, a chemokine, a chemokine receptor, an inhibitory protein, a kinase, a G protein-coupled receptor or a toxin.

### Claim 17 (depends on 1)

The method according to claim 1, wherein the first immunoglobulin chain variable domain is selected from the group consisting of: a VL, a V-NAR, an scFv, a Fab fragment, a F(ab′)2 fragment, a VHH and a VH.

### Claim 18 (depends on 17)

The method according to claim 17, wherein the second immunoglobulin chain variable domain is selected from the group consisting of: a VL, a V-NAR, an scFv, a Fab fragment, a F(ab′)2 fragment, a VHH and a VH.

### Claim 19 (depends on 1)

The method according to claim 1, wherein the labile peptide linker comprises a sequence selected from the group consisting of SEQ ID NOS: 2 to 5.

### Claim 20 (depends on 19)

The method according to claim 19 wherein the labile peptide linker consists of a sequence selected from the group consisting of SEQ ID NOS: 2 to 5.
